Clinical Trials & Research
Clinical Trials & Research
Esophageal and Lung Institute
Diseases of the esophagus and chest affect millions of Americans. Over 200,000 people will be diagnosed with lung cancer and an additional 18,000 with esophageal cancer this year. Most notably, cancers of the esophagus and lungs have some of the highest mortality rates.
Despite the chilling statistics, the team at the Esophageal and Lung Institute uses a multi-disciplinary approach to treating patients. Research efforts at the Institute are diverse and include understanding and managing esophageal disease progression with special emphasis on esophageal cancer, providing novel treatment approaches to gastroesophageal reflux disease (GERD) and achalasia, and various studies focusing on the detection and treatment of lung cancer.
The Esophageal and Lung Institute research team conducts a full spectrum of research initiatives including basic science, translational, and clinical trials to develop a greater understanding of disease progression, prevention, and possible treatments. Through various internally and industry sponsored clinical trials, patients are provided with opportunities to enroll in the newest and most promising approaches to treatment.
Additionally, two tissue banking efforts are underway to provide current patients with an opportunity to lay the groundwork for future discovery.
Active Clinical Trials
- Checkmate 649 Trials
- Lung Cancer Clinical Trials
- A Phase II Trial of modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia.
- CA209577 A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 577)
- Esophageal Disease Tissue Bank for the Esophageal and Lung Institute
- Monitoring of Esophageal Cancer using B-AMP Serum Biomarker Panel
- TCREG-001-00-V2-1209: A Registry of Caris Life Sciences® Molecular Intelligence™ Service (Biomarker Assessment Results) Intended for Correlation with Cancer Clinical Outcomes
- A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim? Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD)
- AIM 3: Determining In Vivo Espression Levels of Hedgehog (Hh) and Bone Morphogenetic Protein 4 (BMP4) Pathway Proteins and Their Downstream Targets in Biopsy Samples of Esophageal Squamous Epithelium From Gastroesophageal Reflux Disease (GERD) Patients With and Without Barrett’s Esophagus (AIM 3)
Contact the Research Team
Blair Jobe, MD, FACS, Director of ELI
Ali Zaidi, MD, Research Director
Kelli Davis, MSN, RN, OCN, Administrative Director, Research
Emily J. Lloyd, CCRC, Clinical Research Manager – Benign/Tissue Banking
Mara A. Yerk, Clinical Research Manager - Oncology